BotuGel™: A proprietary RTGel-based formulation with BOTOX®* (onabotulinumtoxin A) in development for the treatment of overactive bladder (OAB)
OAB is a common, often disabling condition associated with considerable negative impact on quality of life. OAB results in an uncontrolled urge to urinate, frequent urination, and, in many patients, uncontrollable leakage of urine. Standard first-line pharmacologic treatment for OAB is anticholinergic pills; however, the majority of patients stop taking the pills within one year due to an inadequate response to, or intolerance of, the medication. BOTOX® injection into the bladder is approved as a therapy for OAB.
In October 2016, UroGen granted an exclusive worldwide license to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, to research, develop, manufacture and commercialize pharmaceutical products that contain UroGen Pharma’s proprietary RTGelTM and clostridial toxins, including BOTOX. Allergan is conducting a Phase 2 clinical trial of RTGel™ in combination with BOTOX for the treatment of overactive bladder, with the potential to evolve from multiple injections of BOTOX into the bladder to a single instillation. Under the terms of the license agreement, UroGen Pharma is eligible to receive additional payments from Allergan related to the achievement of certain development, regulatory and commercial milestones, in addition to royalties on potential net sales.
*BOTOX is a registered trademark of Allergan Pharmaceuticals
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001